Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00357968 · ClinicalTrials.gov registry record · Phase 2
Trial in Subjects Undergoing Cardiac Catheterization With Planned Percutaneous Coronary Intervention With Stenting
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 201
- Enrollment target
NCT00357968: Completed Phase 2 study, sponsored by Eli Lilly and Company.
NCT00357968 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 201 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (51% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00357968, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 201 participants
- Enrollment target
Study Summary
The purpose of this study is to provide information of the relative potency of prasugrel and clopidogrel on platelet function studies, inflammation, and myocyte necrosis in subjects undergoing elective percutaneous coronary intervention (PCI).
Primary Outcome
IPA was defined as (1 - \[maximal platelet aggregation(MPA) at 6 hours after study drug treatment\]/\[MPA before drug treatment\]) x 100.
Interventions
- DRUG Clopidogrel
- DRUG Prasugrel
- DRUG Placebo for Prasugrel
- DRUG Placebo for Clopidogrel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 201 participants |
| Start Date | 2006-08 |
| Est. Completion | 2007-06 |
| Phase | Phase 2 |
What the finished NCT00357968 record still lists
NCT00357968 is an interventional study that assigns participants to a tested intervention. The registered 201 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (51% higher).
The record links to 0 conditions, and to 4 interventions - of which Clopidogrel is the first listed.
NCT00357968 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00357968 about?
NCT00357968 is a clinical study titled "Trial in Subjects Undergoing Cardiac Catheterization With Planned Percutaneous Coronary Intervention With Stenting". The purpose of this study is to provide information of the relative potency of prasugrel and clopidogrel on platelet function studies, inflammation, and myocyte necrosis in subjects undergoing elective percutaneous coronary intervention (PCI).
What is the current status of trial NCT00357968?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 201 participants. The study started on 2006-08. Estimated completion is 2007-06.
What interventions are being tested in trial NCT00357968?
The interventions under investigation include: Clopidogrel (DRUG), Prasugrel (DRUG), Placebo for Prasugrel (DRUG), Placebo for Clopidogrel (DRUG).
Who is sponsoring clinical trial NCT00357968?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00357968's enrollment target sits among peer trials
201 302nd of 2000 higher than 1,697 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04422652 · 201 participants · Phase 2
Combination of Novel Therapies for CKD Comorbid Depression
- NCT05327114 · 201 participants · Phase 2
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- NCT06099769 · 201 participants · Phase 2
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
- NCT06274528 · 201 participants · Phase 2
DORA and LP in Alzheimer's Disease Biomarkers
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia